HOME > Drug Discovery > Lead Discovery

Our discovery group is a tightly integrated interdisciplinary team of scientists with expertise in medicinal chemistry, structural and computational drug design, biochemistry, molecular and cell biology. The group applies structural and computational approaches to design candidate drugs against targets. The aim is to rapidly identify promising lead candidates by combining drug design tools, along with biological, pharmacological and metabolic assays. Then the biophysical and biology tools were applied to investigate the mechanism of action for the leads, with innovative chemistry to optimize the lead structures. The pharmacology and drug metablism were used to quickly develop these leads into drug candidates. We believe this approach-our unique combination of scientific excellence, accelerates the processes of lead generation and optimization to create the novel drug candidates.

Drug discovery procedure integrated by the 3“I” platforms (In silico, In Vitro, In Vivo)

- Lead discovery, as a lead-package including the compound, In Vitro activities, ADME/T profiles, safety issues, In Vivo efficacy and other profiles, is available to the clients from target analysis, library screening (in silico, in vitro, in vivo), to optimization, hit-to-lead optimization, to preclinical evaluation etc.

- Our strength rests in a full spectrum of chemistry optimization, ADME/T, and discovery biology solutions, consultant and services, which can expedite drug discovery and development programs at fairly lower costs by reduced staffing levels and tightened budgets, .

- Our approach ensures fast, flexible, customer-oriented solutions and services reinforced by strong project management and scientific expertise. We can perform the cutting-edge technologies to find the leads, develop and optimize the next generation inhibitors for the clients.